Description

Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver.

Investigational Activity

Pirfenidone for idiopathic pulmonary fibrosis (IPF) has been studied in multiple Phase 2 clinical trials.

We completed enrollment for CAPACITY, a Phase 3 clinical program evaluating pirfenidone in patients with IPF, in May 2007.

Investigational, not an FDA approved product.